Straits Times Index
3,292.74 +26.79 (+0.82%) Nikkei
38,162.58 +88.60 (+0.23%) Hang Seng
18,859.60 +321.79 (+1.74%) FTSE 100
8,381.35 +27.30 (+0.33%) Bitcoin USD
62,959.97 +1,473.70 (+2.40%) CMC Crypto 200
1,351.22 +51.12 (+3.93%)
Revolution Medicines, Inc. (RVMD)
After hours:
- Insider Monkey
Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript
Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Earnings Call Transcript May 8, 2024 Revolution Medicines, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to Revolution Medicine’s First Quarter 2024 Earnings Conference […]
- GuruFocus.com
Revolution Medicines Inc (RVMD) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Explore key insights from Revolution Medicines' Q1 2024 earnings, focusing on R&D progress and financial metrics.
- GlobeNewswire
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
Revolution Medicines to hold webcast today at 4:30 p.m. Eastern TimeREDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) multi-select
